3-acetylchrysene | 68723-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-acetylchrysene
• 英文别名: 1-chrysen-3-yl-ethanone；1-Chrysen-3-yl-aethanon；3-Acetylchrysen；1-chrysen-3-ylethanone
• CAS: 68723-55-7
• 化学式: C₂₀H₁₄O
• 分子量: 270.331
• InChiKey: OARMMULWJINVQP-UHFFFAOYSA-N

物化性质

• 熔点：
  158 °C(Solv: ethanol (64-17-5))
• 沸点：
  496.5±14.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-acetylchrysene 在 sodium hydride 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成
  参考文献：
  名称：

  带有稠合四苯环生色团、,和pyr的二氟硼化β-二酮的光化学辅助合成和光物理性质†

  摘要：

  我们研究了具有氟和pyr骨架（分别为ChB和PyB）的二氟硼化β-二酮（BF 2 DK）在溶液中和固态时的光物理性质。通过改良的光环化方法，由相应的（乙酰苯基）萘乙炔光化学制备作为ChBs关键前体的乙酰基丙烯腈。BF 2的吸收和发射光谱在氯仿和乙腈中获得DKs，并确定了量子产率和荧光寿命。即使在高度浓缩的溶液中也没有来自PyB的准分子荧光。基于对吸收和荧光特征的Lippert-Mataga分析，讨论了ChBs与PyB的光物理性质。研究的BF 2 DKs的荧光状态显示为具有电荷转移特性。由于增强的内部转化过程，荧光量子产率随着溶剂极性的增加而降低。所研究的BF 2的固态荧光量子产率测定了DKs，发现PyB是荧光的，而ChBs的荧光量子产率取决于depend部分的取代位置。

  DOI：

  10.1039/c6pp00089d
• 作为产物：
  描述：

  1-(α-Naphthyl)-2-(4'-acetylphenyl)ethen 在 水合氯醛 、 碘 、 氧气 作用下， 以 正己烷 、 二氯甲烷 、 环己烷 、 苯 为溶剂， 生成 3-acetylchrysene
  参考文献：
  名称：

  带有稠合四苯环生色团、,和pyr的二氟硼化β-二酮的光化学辅助合成和光物理性质†

  摘要：

  我们研究了具有氟和pyr骨架（分别为ChB和PyB）的二氟硼化β-二酮（BF 2 DK）在溶液中和固态时的光物理性质。通过改良的光环化方法，由相应的（乙酰苯基）萘乙炔光化学制备作为ChBs关键前体的乙酰基丙烯腈。BF 2的吸收和发射光谱在氯仿和乙腈中获得DKs，并确定了量子产率和荧光寿命。即使在高度浓缩的溶液中也没有来自PyB的准分子荧光。基于对吸收和荧光特征的Lippert-Mataga分析，讨论了ChBs与PyB的光物理性质。研究的BF 2 DKs的荧光状态显示为具有电荷转移特性。由于增强的内部转化过程，荧光量子产率随着溶剂极性的增加而降低。所研究的BF 2的固态荧光量子产率测定了DKs，发现PyB是荧光的，而ChBs的荧光量子产率取决于depend部分的取代位置。

  DOI：

  10.1039/c6pp00089d

文献信息

• Crysene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719046A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl, ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的这些醚物可能总共不超过30个碳原子）；它们的醚，酯；酸盐；其中Ar是蒽或取代蒽环系；R.sup.1含有不超过八个碳原子，并且是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基，##STR2##是一个五元或六元饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Crysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04719048A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the ame or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，在总共不超过30个碳原子的情况下）;其醚，酯;酸加成盐;其中Ar是蒽或取代蒽环系统; R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1; R.sup.5为氢; R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代; R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基; ##STR2##是一个五元或六元饱和碳环; R.sup.10为氢，甲基或羟甲基; R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基; R.sup.14为氢，甲基，羟基或羟甲基。
• Chrysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04810727A1

  公开（公告）日：1989-03-07

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; --C--C-- is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式(I) ArCH.sub.2R.sup.1(I)化合物或其单甲基或单乙基醚（式(I)化合物包括这些醚，总碳原子数不超过30）；醚，酯；其酸加成盐；其中Ar是蒽或取代蒽环系统；R.sup.1不超过八个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-3烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；--C--C--是一个五元或六元饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Polycyclic aromatic compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0125701A2

  公开（公告）日：1984-11-21

  Compounds of the formula (I) or monomethyl or monoethyl ethers thereof, the compounds of formula (I) including their ethers containing no more than 30 carbon atoms in total, or esters or salts thereof; wherein Aris perylene,fluoranthene, chrysene, pyrene or triphenylene, optionally substituted by one or two substituents, or when Ar is anthracene or phenanthrene optionally substituted by one, two or three substituents; said substituents containing not more than four carbon atoms in total when taken together being the same or different and are selected from halogen; cyano; C1-4alkyl or C1-4alkoxy, each optionally substituted by hydroxy or C1-2alkoxy; halogen substituted Cl-2alkyl or C1-2alkoxy; halogen substituted Ci-2 alkyl or C1-2alkoxy; a group S(O)nR2 wherein n is an integer 0,1 or 2 and R2 is C1-2alkyl optionally substituted by hydroxy or C1- 2alkoxy; or Ar is optionally substituted by a group NR3R4 containing not more than 5 carbon atoms wherein R3 and R' are the same or different and each is a Ci-3alkyl group or NR3R4 forms a five-or six-membered heterocyclic ring optionally containing one or two additional heteroatoms; R' contains not more than eight carbon atoms and is a group or wherein m is 0 or 1; R5 is hydrogen or methyl; R6 and R' are the same or different and each is hydrogen or C1-3alkyl optionally substituted by hydroxy; R8 and R9 are the same or different and each is hydrogen or Ci-3alkyl; -C-C- is a five-or six-membered saturated carbocyclic ring; R10 is hydrogen, methyl or hydroxymethyl; R", R12 and R13 are the same or different and each is hydrogen or methyl; R14 is hydrogen, methyl, hydroxy, or hydroxymethyl; and provided that when Ar is 6-chrysenyl, 3- or 7-fluoranthenyl, 2-triphenylenyl, or 1- or 9-anthracenyl optionally substituted by one or two substituents as hereinbefore defined; other than optionally substituted butyl or butoxy R6 is C1-3alkyl optionally substituted by hydroxy; R7 is hydrogen, C1-3alkyl or hydroxymethyl; R'to R12 and R" are as hereinbefore defined; R13 is hydrogen; and m is 0; R5 is methyl, are disclosed as having biocidal and, in particular, antitumour activity. Methods for preparing the compounds, formulations containing them and their use in medicine are also described.

  式(I)化合物 或其单甲基醚或单乙基醚，式（I）化合物包括其总计含有不超过 30 个碳原子的醚，或其酯或盐；其中 Ar 为过ylene、fluoranthene、chrysene、pyrene 或 triphenylene，可任选被一个或两个取代基取代，或当 Ar 为 anthracene 或 phenanthrene 时，可任选被一个、两个或三个取代基取代；所述取代基在一起时总计含有不超过四个碳原子，可相同或不同，选自卤素、氰基、C1-4 烷基或 C1-4 烷氧基，各自可任选被羟基或 C1-2 烷氧基取代；卤素取代的 Cl-2 烷基或 C1-2 烷氧基；卤素取代的 C1-2 烷基或 C1-2 烷氧基；C1-4 烷基或 C1-4 烷氧基，各自可选被羟基或 C1-2 烷氧基取代；卤素取代的 Cl-2 烷基或 C1-2 烷氧基；卤素取代的 Ci-2 烷基或 C1-2 烷氧基；基团 S(O)nR2，其中 n 为整数 0、1 或 2，R2 为可选被羟基或 C1-2 烷氧基取代的 C1-2 烷基；或 Ar 被含有不超过 5 个碳原子的基团 NR3R4 任选取代，其中 R3 和 R'相同或不同，且各自为 Ci-3 烷基或 NR3R4 构成五或六元杂环，可任选含有一个或两个额外的杂原子；R'含有不超过 8 个碳原子，且是一个基团 或 其中 m 为 0 或 1； R5 是氢或甲基； R6 和 R' 相同或不同，各自为氢或任选被羟基取代的 C1-3 烷基； R8和R9相同或不同，各自为氢或Ci-3烷基； -C-C-是五或六元饱和碳环；R10 是氢、甲基或羟甲基；R"、R12 和 R13 相同或不同，且各自是氢或甲基；R14 是氢、甲基、羟基或羟甲基；且当 Ar 是 6-丙烯腈基、3-或 7-氟苯基、2-三苯烯基或 1-或 9-蒽基时，可任选被一个或两个如前定义的取代基取代；除任选取代的丁基或丁氧基外，R6 是任选被羟基取代的 C1-3 烷基；R7 是氢、C1-3 烷基或羟甲基；R'至 R12 和 R "如前定义；R13 是氢；m 是 0；R5 是甲基。此外，还描述了制备这些化合物的方法、含有这些化合物的制剂及其在医学中的用途。
• 2-[(Arylmethyl)amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding
  作者：Kenneth W. Bair、C. Webster Andrews、Richard L. Tuttle、Vincent C. Knick、Michael Cory、David D. McKee

  DOI：10.1021/jm00111a010

  日期：1991.7

  The effects of variation of aromatic ring size, shape, and side-chain position on antitumor activity and DNA binding in a series of carbocyclic 2-[(arylmethyl)amino]-2-methyl-1,3-propanediols (AMAPs) were examined. In general, the interaction of AMAPs with DNA increases as the intercalating ring system grows in area, with three distinct binding levels evident. Isomers from a specific ring system appear to bind DNA similarly. DNA binding is not the sole criterion for antitumor activity for the AMAPs studied; the magnitude of the DELTA-T(m) does not correlate with the antitumor activity observed. Significant in vivo P388 activity was seen for AMAP congeners from several tetracyclic ring systems. However, isomers from each of the specific ring systems produced a wide range of in vivo P388 activity. Thus, AMAP antitumor activity is not a function of the ring system per se, but rather appears to be related to the shape of the specific molecule. Three AMAP congeners (crisnatol (770U82, 773U82, and 502U83) are currently in clinical trials.